Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
- Author:
Yuan-Bin HUANG
1
;
Wei-Lin LI
1
;
Man SUN
1
;
Xu DUAN
2
;
Yu-Tong WANG
2
;
Lu-Xin ZHANG
3
;
Zi-Han XIN
2
;
Zhi-Fei YUN
4
;
Bo FAN
1
;
Xian-Cheng LI
1
Author Information
- Publication Type:Journal Article
- Keywords: androgen deprivation therapy; coronavirus disease 2019; meta-analysis; prostate cancer; severe acute respiratory syndrome coronavirus 2
- MeSH: Male; Humans; Prostatic Neoplasms/chemically induced*; Androgen Antagonists/adverse effects*; COVID-19; Androgens/therapeutic use*; SARS-CoV-2
- From: Asian Journal of Andrology 2023;25(3):366-374
- CountryChina
- Language:English
- Abstract: Studies have investigated the effects of androgen deprivation therapy (ADT) use on the incidence and clinical outcomes of coronavirus disease 2019 (COVID-19); however, the results have been inconsistent. We searched the PubMed, Medline, Cochrane, Scopus, and Web of Science databases from inception to March 2022; 13 studies covering 84 003 prostate cancer (PCa) patients with or without ADT met the eligibility criteria and were included in the meta-analysis. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CIs) to explore the association between ADT use and the infection risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severity of COVID-19. After synthesizing the evidence, the pooled RR in the SARS-CoV-2 positive group was equal to 1.17, and the SARS-CoV-2 positive risk in PCa patients using ADT was not significantly different from that in those not using ADT (P = 0.544). Moreover, no significant results concerning the beneficial effect of ADT on the rate of intensive care unit admission (RR = 1.04, P = 0.872) or death risk (RR = 1.23, P = 0.53) were found. However, PCa patients with a history of ADT use had a markedly higher COVID-19 hospitalization rate (RR = 1.31, P = 0.015) than those with no history of ADT use. These findings indicate that ADT use by PCa patients is associated with a high risk of hospitalization during infection with SARS-CoV-2. A large number of high quality studies are needed to confirm these results.
